Explore the Potential with AI-Driven Innovation
The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.
The compounds are cherry-picked from the vast virtual chemical space of over 60B molecules. The synthesis and delivery of compounds is facilitated by our partner Reaxense.
In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our strategy employs molecular simulations to explore an extensive range of proteins, capturing their dynamics both individually and within complexes with other proteins. Through ensemble virtual screening, we address proteins' conformational mobility, uncovering key binding sites at both functional regions and remote allosteric locations. This comprehensive investigation ensures a thorough assessment of all potential mechanisms of action, with the goal of discovering innovative therapeutic targets and lead molecules across across diverse biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P58304
UPID:
VSX2_HUMAN
Alternative names:
Ceh-10 homeodomain-containing homolog; Homeobox protein CHX10
Alternative UPACC:
P58304; A1A4X6
Background:
Visual system homeobox 2 (VSX2), also known as Homeobox protein CHX10, plays a pivotal role in eye development and function. It acts as a transcriptional regulator, binding to DNA to influence gene expression. VSX2 is crucial for the morphogenesis of the sensory retina, differentiation of V2a interneurons, and the development of retinal ganglion cells, which are essential for vision.
Therapeutic significance:
VSX2 is implicated in several eye formation disorders, including Microphthalmia, isolated, 2, Microphthalmia with cataracts and iris abnormalities, and Microphthalmia, isolated, with coloboma, 3. These conditions range from minor eye size anomalies to complete absence of ocular tissues. Understanding the role of VSX2 could open doors to potential therapeutic strategies for these visual impairments.